Analgesics⏵
Antiandrogens⏵
Antihistamines⏵
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle⏵
Melatonin
Metformin
Minerals⏵
Monoclonals⏵
Mpro inhibitors⏵
Naso/orophar..⏵
Nigella Sativa
Nitazoxanide
PPIs
Quercetin
RdRp inhibitors⏵
Thermotherapy
Vitamins⏵
More⏵

Other
Feedback
Home
 
Top
..
Results
..
All vadadustat studies
..
Meta analysis
..
Feedback
Home
←
next
study
→
previous
study
c19early.org COVID-19 treatment researchVadadustatVadadustat (more..)
Metformin Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta
Ivermectin Meta Thermotherapy Meta
Melatonin Meta
Home Adoption Other Treatments
@CovidAnalysis
All Studies   All Outcomes       

Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19)

Bobrow et al., NCT04478071, VSTAT, NCT04478071
Mar 2025  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality -3% Improvement Relative Risk Progression 16% Recovery 8% Vadadustat  VSTAT  LATE TREATMENT  DB RCT Is late treatment with vadadustat beneficial for COVID-19? Double-blind RCT 448 patients in the USA Lower progression with vadadustat (not stat. sig., p=0.36) c19early.org Bobrow et al., NCT04478071, March 2025 Favorsvadadustat Favorscontrol 0 0.5 1 1.5 2+
RCT 448 hospitalized COVID-19 patients in the USA showing no significant differences with vadadustat.
Standard of Care (SOC) for COVID-19 in the study country, the USA, is very poor with very low average efficacy for approved treatments1. Only expensive, high-profit treatments were approved. Low-cost treatments were excluded, reducing the probability of treatment—especially early—due to access and cost barriers, and eliminating complementary and synergistic benefits seen with many low-cost treatments.
Important missing comments or errors? Let us know.
risk of death, 2.7% higher, RR 1.03, p = 1.00, treatment 19 of 221 (8.6%), control 19 of 227 (8.4%), day 28.
risk of progression, 16.2% lower, RR 0.84, p = 0.36, treatment 43 of 216 (19.9%), control 53 of 223 (23.8%), NNT 26, NIAID ordinal score ≥6, day 14.
risk of no recovery, 8.4% lower, RR 0.92, p = 0.60, treatment 58 of 214 (27.1%), control 66 of 223 (29.6%), NNT 40, MSOFA 0, day 14.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Bobrow et al., 25 Mar 2025, Double Blind Randomized Controlled Trial, placebo-controlled, USA, preprint, 1 author, average treatment delay 7.0 days, trial NCT04478071 (history) (VSTAT). Contact: Bentley.J.Bobrow@uth.tmc.edu.
This PaperVadadustatAll
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0